RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors

Haiying Cheng, Yiyu Zou, Jeffrey S. Ross, Kai Wang, Xuewen Liu, Balazs Halmos, Siraj M. Ali, Huijie Liu, Amit K. Verma, Cristina Montagna, Abraham Chachoua, Sanjay Goel, Edward L. Schwartz, Changcheng Zhu, Jidong Shan, Yiting Yu, Kira Gritsman, Roman Yelensky, Doron Lipson, Geoff OttoMatthew Hawryluk, Philip J. Stephens, Vincent A. Miller, Bilal Piperdi, Roman Perez-Soler

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

We identified amplification of RICTOR, a key component of the mTOR complex 2 (mTORC2), as the sole actionable genomic alteration in an 18-year-old never-smoker with lung adenocarcinoma. Amplification of RICTOR occurs in 13% of lung cancers (1,016 cases) in The Cancer Genome Atlas and at a similar frequency in an independent cohort of 1,070 patients identified by genomic profiling. In the latter series, 11% of cases harbored RICTOR amplification as the only relevant genomic alteration. Its oncogenic roles were suggested by decreased lung cancer cell growth both in vitro and in vivo with RICTOR ablation, and the transforming capacity of RICTOR in a Ba/F3-cell system. The mTORC1/2 inhibitors were significantly more active against RICTOR -amplified lung cancer cells as compared with other agents targeting the PI3K–AKT–mTOR pathway. Moreover, an association between RICTOR amplification and sensitivities to mTORC1/2 inhibitors was observed. The index patient has been treated with mTORC1/2 inhibitors that led to tumor stabilization for more than 18 months. Significance: RICTO R amplification may define a novel and unique molecular subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors.

Original languageEnglish (US)
Pages (from-to)1262-1270
Number of pages9
JournalCancer Discovery
Volume5
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Lung Neoplasms
Atlases
Therapeutics
Neoplasms
Genome
mechanistic target of rapamycin complex 1
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. / Cheng, Haiying; Zou, Yiyu; Ross, Jeffrey S.; Wang, Kai; Liu, Xuewen; Halmos, Balazs; Ali, Siraj M.; Liu, Huijie; Verma, Amit K.; Montagna, Cristina; Chachoua, Abraham; Goel, Sanjay; Schwartz, Edward L.; Zhu, Changcheng; Shan, Jidong; Yu, Yiting; Gritsman, Kira; Yelensky, Roman; Lipson, Doron; Otto, Geoff; Hawryluk, Matthew; Stephens, Philip J.; Miller, Vincent A.; Piperdi, Bilal; Perez-Soler, Roman.

In: Cancer Discovery, Vol. 5, No. 12, 01.12.2015, p. 1262-1270.

Research output: Contribution to journalArticle

Cheng, Haiying ; Zou, Yiyu ; Ross, Jeffrey S. ; Wang, Kai ; Liu, Xuewen ; Halmos, Balazs ; Ali, Siraj M. ; Liu, Huijie ; Verma, Amit K. ; Montagna, Cristina ; Chachoua, Abraham ; Goel, Sanjay ; Schwartz, Edward L. ; Zhu, Changcheng ; Shan, Jidong ; Yu, Yiting ; Gritsman, Kira ; Yelensky, Roman ; Lipson, Doron ; Otto, Geoff ; Hawryluk, Matthew ; Stephens, Philip J. ; Miller, Vincent A. ; Piperdi, Bilal ; Perez-Soler, Roman. / RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. In: Cancer Discovery. 2015 ; Vol. 5, No. 12. pp. 1262-1270.
@article{54ac4498c7a04fe39c87ce2e73ae697f,
title = "RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors",
abstract = "We identified amplification of RICTOR, a key component of the mTOR complex 2 (mTORC2), as the sole actionable genomic alteration in an 18-year-old never-smoker with lung adenocarcinoma. Amplification of RICTOR occurs in 13{\%} of lung cancers (1,016 cases) in The Cancer Genome Atlas and at a similar frequency in an independent cohort of 1,070 patients identified by genomic profiling. In the latter series, 11{\%} of cases harbored RICTOR amplification as the only relevant genomic alteration. Its oncogenic roles were suggested by decreased lung cancer cell growth both in vitro and in vivo with RICTOR ablation, and the transforming capacity of RICTOR in a Ba/F3-cell system. The mTORC1/2 inhibitors were significantly more active against RICTOR -amplified lung cancer cells as compared with other agents targeting the PI3K–AKT–mTOR pathway. Moreover, an association between RICTOR amplification and sensitivities to mTORC1/2 inhibitors was observed. The index patient has been treated with mTORC1/2 inhibitors that led to tumor stabilization for more than 18 months. Significance: RICTO R amplification may define a novel and unique molecular subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors.",
author = "Haiying Cheng and Yiyu Zou and Ross, {Jeffrey S.} and Kai Wang and Xuewen Liu and Balazs Halmos and Ali, {Siraj M.} and Huijie Liu and Verma, {Amit K.} and Cristina Montagna and Abraham Chachoua and Sanjay Goel and Schwartz, {Edward L.} and Changcheng Zhu and Jidong Shan and Yiting Yu and Kira Gritsman and Roman Yelensky and Doron Lipson and Geoff Otto and Matthew Hawryluk and Stephens, {Philip J.} and Miller, {Vincent A.} and Bilal Piperdi and Roman Perez-Soler",
year = "2015",
month = "12",
day = "1",
doi = "10.1158/2159-8290.CD-14-0971",
language = "English (US)",
volume = "5",
pages = "1262--1270",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors

AU - Cheng, Haiying

AU - Zou, Yiyu

AU - Ross, Jeffrey S.

AU - Wang, Kai

AU - Liu, Xuewen

AU - Halmos, Balazs

AU - Ali, Siraj M.

AU - Liu, Huijie

AU - Verma, Amit K.

AU - Montagna, Cristina

AU - Chachoua, Abraham

AU - Goel, Sanjay

AU - Schwartz, Edward L.

AU - Zhu, Changcheng

AU - Shan, Jidong

AU - Yu, Yiting

AU - Gritsman, Kira

AU - Yelensky, Roman

AU - Lipson, Doron

AU - Otto, Geoff

AU - Hawryluk, Matthew

AU - Stephens, Philip J.

AU - Miller, Vincent A.

AU - Piperdi, Bilal

AU - Perez-Soler, Roman

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We identified amplification of RICTOR, a key component of the mTOR complex 2 (mTORC2), as the sole actionable genomic alteration in an 18-year-old never-smoker with lung adenocarcinoma. Amplification of RICTOR occurs in 13% of lung cancers (1,016 cases) in The Cancer Genome Atlas and at a similar frequency in an independent cohort of 1,070 patients identified by genomic profiling. In the latter series, 11% of cases harbored RICTOR amplification as the only relevant genomic alteration. Its oncogenic roles were suggested by decreased lung cancer cell growth both in vitro and in vivo with RICTOR ablation, and the transforming capacity of RICTOR in a Ba/F3-cell system. The mTORC1/2 inhibitors were significantly more active against RICTOR -amplified lung cancer cells as compared with other agents targeting the PI3K–AKT–mTOR pathway. Moreover, an association between RICTOR amplification and sensitivities to mTORC1/2 inhibitors was observed. The index patient has been treated with mTORC1/2 inhibitors that led to tumor stabilization for more than 18 months. Significance: RICTO R amplification may define a novel and unique molecular subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors.

AB - We identified amplification of RICTOR, a key component of the mTOR complex 2 (mTORC2), as the sole actionable genomic alteration in an 18-year-old never-smoker with lung adenocarcinoma. Amplification of RICTOR occurs in 13% of lung cancers (1,016 cases) in The Cancer Genome Atlas and at a similar frequency in an independent cohort of 1,070 patients identified by genomic profiling. In the latter series, 11% of cases harbored RICTOR amplification as the only relevant genomic alteration. Its oncogenic roles were suggested by decreased lung cancer cell growth both in vitro and in vivo with RICTOR ablation, and the transforming capacity of RICTOR in a Ba/F3-cell system. The mTORC1/2 inhibitors were significantly more active against RICTOR -amplified lung cancer cells as compared with other agents targeting the PI3K–AKT–mTOR pathway. Moreover, an association between RICTOR amplification and sensitivities to mTORC1/2 inhibitors was observed. The index patient has been treated with mTORC1/2 inhibitors that led to tumor stabilization for more than 18 months. Significance: RICTO R amplification may define a novel and unique molecular subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84960131361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960131361&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0971

DO - 10.1158/2159-8290.CD-14-0971

M3 - Article

C2 - 26370156

AN - SCOPUS:84960131361

VL - 5

SP - 1262

EP - 1270

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 12

ER -